Perrigo Past Earnings Performance
Past criteria checks 0/6
Perrigo's earnings have been declining at an average annual rate of -57%, while the Pharmaceuticals industry saw earnings growing at 12.5% annually. Revenues have been declining at an average rate of 3.5% per year.
Key information
-57.0%
Earnings growth rate
-56.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | -3.5% |
| Return on equity | -2.7% |
| Net Margin | -2.9% |
| Next Earnings Update | 09 May 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Perrigo makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 4,452 | -131 | 1,161 | 123 |
| 01 Oct 22 | 4,401 | -86 | 1,126 | 121 |
| 02 Jul 22 | 4,344 | -88 | 1,129 | 119 |
| 02 Apr 22 | 4,203 | -135 | 1,108 | 120 |
| 31 Dec 21 | 4,139 | -131 | 1,108 | 122 |
| 02 Oct 21 | 4,087 | -215 | 1,146 | 125 |
| 03 Jul 21 | 4,047 | -135 | 1,126 | 128 |
| 03 Apr 21 | 4,015 | -11 | 1,105 | 125 |
| 31 Dec 20 | 4,088 | 44 | 1,100 | 122 |
| 26 Sep 20 | 4,358 | 77 | 1,096 | 148 |
| 27 Jun 20 | 4,546 | 143 | 1,109 | 162 |
| 28 Mar 20 | 4,746 | 140 | 1,147 | 175 |
| 31 Dec 19 | 3,870 | 159 | 1,095 | 119 |
| 28 Sep 19 | 4,710 | 247 | 1,157 | 173 |
| 29 Jun 19 | 4,652 | 87 | 1,142 | 172 |
| 30 Mar 19 | 4,689 | 114 | 1,127 | 220 |
| 31 Dec 18 | 4,732 | 131 | 1,124 | 219 |
| 29 Sep 18 | 4,820 | 123 | 1,133 | 221 |
| 30 Jun 18 | 4,918 | 235 | 1,158 | 216 |
| 31 Mar 18 | 4,969 | 129 | 1,158 | 166 |
| 31 Dec 17 | 4,946 | 120 | 1,146 | 168 |
| 30 Sep 17 | 4,994 | -1,313 | 1,161 | 162 |
| 01 Jul 17 | 5,025 | -2,947 | 1,154 | 174 |
| 01 Apr 17 | 5,127 | -3,412 | 1,177 | 179 |
| 31 Dec 16 | 5,281 | -4,013 | 1,206 | 184 |
| 01 Oct 16 | 5,308 | -2,872 | 1,241 | 189 |
| 02 Jul 16 | 5,320 | -1,021 | 1,289 | 180 |
Quality Earnings: PRGO N is currently unprofitable.
Growing Profit Margin: PRGO N is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: PRGO N is unprofitable, and losses have increased over the past 5 years at a rate of 57% per year.
Accelerating Growth: Unable to compare PRGO N's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PRGO N is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (8.1%).
Return on Equity
High ROE: PRGO N has a negative Return on Equity (-2.7%), as it is currently unprofitable.